Literature DB >> 18070884

Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.

Carmen J Tartari1, Rosalind H Gunby, Addolorata M L Coluccia, Roberta Sottocornola, Barbara Cimbro, Leonardo Scapozza, Arianna Donella-Deana, Lorenzo A Pinna, Carlo Gambacorti-Passerini.   

Abstract

NPM/ALK is an oncogenic fusion protein expressed in approximately 50% of anaplastic large cell lymphoma cases. It derives from the t(2;5)(p23;q35) chromosomal translocation that fuses the catalytic domain of the tyrosine kinase, anaplastic lymphoma kinase (ALK), with the dimerization domain of the ubiquitously expressed nucleophosmin (NPM) protein. Dimerization of the ALK kinase domain leads to its autophosphorylation and constitutive activation. Activated NPM/ALK stimulates downstream survival and proliferation signaling pathways leading to malignant transformation. Herein, we investigated the molecular mechanisms of autoactivation of the catalytic domain of ALK. Because kinases are typically regulated by autophosphorylation of their activation loops, we systematically mutated (Tyr --> Phe) three potential autophosphorylation sites contained in the "YXXXYY" motif of the ALK activation loop, and determined the effect of these mutations on the catalytic activity and biological function of NPM/ALK. We observed that mutation of both the second and third tyrosine residues (YFF mutant) did not affect the kinase activity or transforming ability of NPM/ALK. In contrast, mutation of the first and second (FFY), first and third (FYF), or all three (FFF) tyrosine residues impaired both kinase activity and transforming ability of NPM/ALK. Furthermore, a DFF mutant, in which the aspartic residue introduces a negative charge similar to a phosphorylated tyrosine, possessed catalytic activity similar to the YFF mutant. Together, our findings indicate that phosphorylation of the first tyrosine of the YXXXYY motif is necessary for the autoactivation of the ALK kinase domain and the transforming activity of NPM/ALK.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070884     DOI: 10.1074/jbc.M706067200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

2.  Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.

Authors:  Bin Shi; Deeksha Vishwamitra; J Gabrielle Granda; Thomas Whitton; Ping Shi; Hesham M Amin
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

3.  Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.

Authors:  Fang Wu; Peng Wang; Jingdong Zhang; Leah C Young; Raymond Lai; Liang Li
Journal:  Mol Cell Proteomics       Date:  2010-04-14       Impact factor: 5.911

4.  The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.

Authors:  Samar A Hegazy; Peng Wang; Mona Anand; Robert J Ingham; Pascal Gelebart; Raymond Lai
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

5.  The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.

Authors:  Linda F Epstein; Hao Chen; Renee Emkey; Douglas A Whittington
Journal:  J Biol Chem       Date:  2012-08-29       Impact factor: 5.157

6.  Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry.

Authors:  Peng Wang; Fang Wu; Yupo Ma; Liang Li; Raymond Lai; Leah C Young
Journal:  J Biol Chem       Date:  2009-11-02       Impact factor: 5.157

Review 7.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

Review 8.  Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.

Authors:  Andres Morales La Madrid; Andres Morales La Madrid; Nicholas Campbell; Sonali Smith; Susan L Cohn; Ravi Salgia
Journal:  Target Oncol       Date:  2012-09-12       Impact factor: 4.493

9.  IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.

Authors:  Ping Shi; Raymond Lai; Quan Lin; Abid S Iqbal; Leah C Young; Larry W Kwak; Richard J Ford; Hesham M Amin
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.